SI3470397T1 - Kristalinične oblike zaviralca prolil hidroksilaze - Google Patents

Kristalinične oblike zaviralca prolil hidroksilaze

Info

Publication number
SI3470397T1
SI3470397T1 SI201331973T SI201331973T SI3470397T1 SI 3470397 T1 SI3470397 T1 SI 3470397T1 SI 201331973 T SI201331973 T SI 201331973T SI 201331973 T SI201331973 T SI 201331973T SI 3470397 T1 SI3470397 T1 SI 3470397T1
Authority
SI
Slovenia
Prior art keywords
crystalline forms
prolyl hydroxylase
hydroxylase inhibitor
inhibitor
prolyl
Prior art date
Application number
SI201331973T
Other languages
English (en)
Slovenian (sl)
Inventor
Claudia Witschi
Jung Min Park
Michael D. Thompson
Michael John Martinelli
David A. Yeowell
Michael P. Arend
Original Assignee
Fibrogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48857025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3470397(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen, Inc. filed Critical Fibrogen, Inc.
Publication of SI3470397T1 publication Critical patent/SI3470397T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
SI201331973T 2012-07-16 2013-07-15 Kristalinične oblike zaviralca prolil hidroksilaze SI3470397T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261672191P 2012-07-16 2012-07-16
US201361768297P 2013-02-22 2013-02-22
US201361832566P 2013-06-07 2013-06-07
EP18189607.7A EP3470397B1 (en) 2012-07-16 2013-07-15 Crystalline forms of a prolyl hydroxylase inhibitor

Publications (1)

Publication Number Publication Date
SI3470397T1 true SI3470397T1 (sl) 2022-07-29

Family

ID=48857025

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201331973T SI3470397T1 (sl) 2012-07-16 2013-07-15 Kristalinične oblike zaviralca prolil hidroksilaze
SI201331143T SI2872488T1 (sl) 2012-07-16 2013-07-15 Kristalinične oblike inhibitorja prolil hidroksilaze

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201331143T SI2872488T1 (sl) 2012-07-16 2013-07-15 Kristalinične oblike inhibitorja prolil hidroksilaze

Country Status (29)

Country Link
US (5) US9115085B2 (show.php)
EP (3) EP4029854A1 (show.php)
JP (2) JP6491093B2 (show.php)
KR (4) KR20220164068A (show.php)
CN (9) CN104684897A (show.php)
AU (1) AU2013290438C1 (show.php)
BR (1) BR112015001101A2 (show.php)
CA (1) CA2879242C (show.php)
CY (2) CY1120805T1 (show.php)
DK (2) DK3470397T3 (show.php)
ES (2) ES2689430T3 (show.php)
FR (1) FR22C1030I2 (show.php)
HK (1) HK1243409A1 (show.php)
HR (2) HRP20181751T1 (show.php)
HU (2) HUE057925T2 (show.php)
IL (1) IL236626B (show.php)
IN (1) IN2015KN00262A (show.php)
LT (3) LT3470397T (show.php)
MX (1) MX355428B (show.php)
MY (1) MY182428A (show.php)
NO (1) NO2022024I1 (show.php)
NZ (1) NZ704662A (show.php)
PL (2) PL2872488T3 (show.php)
PT (2) PT3470397T (show.php)
RS (2) RS57795B1 (show.php)
SG (3) SG11201500236SA (show.php)
SI (2) SI3470397T1 (show.php)
SM (2) SMT201800565T1 (show.php)
WO (1) WO2014014835A2 (show.php)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100932169B1 (ko) 2003-06-06 2009-12-16 피브로겐, 인크. 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
SMT201800565T1 (it) * 2012-07-16 2018-11-09 Fibrogen Inc Forme cristalline di un inibitore di prolil idrossilasi
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
BR112015001106B1 (pt) 2012-07-16 2021-11-09 Fibrogen, Inc Métodos para a produção de compostos de isoquinolina
RS60464B1 (sr) 2013-06-06 2020-07-31 Fibrogen Inc Farmaceutske formulacije inhibitora hif hidroksilaze
CN103694172A (zh) * 2013-12-26 2014-04-02 辽宁亿灵科创生物医药科技有限公司 含氮杂芳基化合物的衍生物
WO2016045125A1 (en) 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CN104892509B (zh) * 2015-06-04 2018-03-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106916105A (zh) * 2015-12-28 2017-07-04 徐州万邦金桥制药有限公司 一种纯化可博美的方法
WO2017143131A1 (en) * 2016-02-19 2017-08-24 Cornell University Hif-stabilization and prevention of hyperoxia-induced neonatal lung disease
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
CN108017583B (zh) * 2016-11-01 2021-04-06 徐州万邦金桥制药有限公司 一种可博美的制备方法
CN107382986B (zh) * 2017-08-02 2022-09-20 江苏艾立康医药科技有限公司 4-羟基-1-甲基异喹啉衍生物及其在增加内源性促红细胞生成素中的用途
CN111511371A (zh) * 2017-08-11 2020-08-07 雷迪博士实验室有限公司 罗沙司他的多晶型物和共晶
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
WO2019042641A1 (en) 2017-09-04 2019-03-07 Sandoz Ag CO-CRYSTAL OF A HIF PROLYL HYDROXYLASE INHIBITOR AVAILABLE ORALLY
WO2019233321A1 (zh) 2018-06-05 2019-12-12 沈阳化工大学 一种三氟乙基硫醚(亚砜)取代苯类化合物及其用途
CN111320583A (zh) * 2018-12-14 2020-06-23 广东东阳光药业有限公司 诺德司他新晶型及其制备方法
CN109369525A (zh) * 2018-12-29 2019-02-22 安礼特（上海）医药科技有限公司 罗沙司它的新晶型及其制备方法
WO2020217190A1 (en) * 2019-04-26 2020-10-29 Dr. Reddy’S Laboratories Limited Process for the purification of roxadustat
CN112679428A (zh) * 2019-10-17 2021-04-20 罗欣药业(上海)有限公司 罗沙司他新晶型及其制备方法
JP2022553706A (ja) * 2019-10-22 2022-12-26 ▲蘇▼州科睿思制▲葯▼有限公司 低酸素誘導因子－プロリルヒドロキシラーゼ阻害剤の結晶形
CN110721185B (zh) * 2019-11-13 2022-04-12 南京市儿童医院 罗沙司他用于心肌保护的用途
CN112961107B (zh) * 2019-12-13 2024-06-25 罗欣药业(上海)有限公司 罗沙司他的晶型及其制备方法
WO2021186356A1 (en) * 2020-03-17 2021-09-23 Cadila Healthcare Limited Formulation comprising hif prolyl hydroxylase inhibitors
CN111205224B (zh) * 2020-04-22 2020-08-25 南京佰麦生物技术有限公司 一种罗沙司他水合物的晶型及其制备方法和应用
CN113754569B (zh) * 2020-06-04 2024-07-02 四川国为制药有限公司 一种中间体化合物及其制备方法和用途
CN111533691A (zh) * 2020-06-08 2020-08-14 重庆三圣实业股份有限公司 一种罗沙司他的制备方法
CN114057643B (zh) * 2020-08-04 2023-02-28 成都苑东生物制药股份有限公司 一种罗沙司他共晶及其制备方法
CN112194624A (zh) * 2020-11-18 2021-01-08 江苏豪森药业集团有限公司 一种异喹啉类化合物的晶型及其制备方法
CN112500344B (zh) * 2020-11-18 2022-07-01 江苏豪森药业集团有限公司 罗沙司他晶型及其制备方法
CN115724796A (zh) * 2021-08-26 2023-03-03 成都苑东生物制药股份有限公司 一种罗沙司他新晶型及其制备方法
CN113956200A (zh) * 2021-12-16 2022-01-21 南京威凯尔生物医药科技有限公司 一种粒径控制的罗沙司他原料药的结晶工艺
CN116410134A (zh) * 2021-12-31 2023-07-11 北京济美堂医药研究有限公司 一种罗沙司他水合物晶体及其制备方法和应用
WO2025111214A1 (en) 2023-11-22 2025-05-30 Fibrogen, Inc. [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds)

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
DE59401923D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
CA2272565A1 (en) 1996-11-27 1998-06-04 Du Pont Pharmaceuticals Company Integrin receptor antagonists
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1315220B1 (it) * 1999-12-13 2003-02-03 Ipm Ind Plastica Monregalese Telone di foglia pluristrato di materia plastica per pacciamature e/ocome barriera di contenimento di sostanze di trattamento in
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
CA2450625A1 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
WO2002101073A2 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
ES2686625T3 (es) 2001-12-06 2018-10-18 Fibrogen, Inc. Métodos para el tratamiento o prevención de la anemia
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
RS58025B1 (sr) 2002-12-16 2019-02-28 Kissei Pharmaceutical Co Ltd Lekovi u čvrstom stanju za oralnu upotrebu
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
KR100932169B1 (ko) * 2003-06-06 2009-12-16 피브로겐, 인크. 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
EP1646611A1 (en) 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
EP1658074B1 (en) 2003-08-01 2012-11-07 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
KR101194123B1 (ko) 2004-03-16 2012-10-24 아사히 가세이 파마 가부시키가이샤 패수딜 함유 제제 및 그 안정성을 개선하는 방법
ES2332798T3 (es) 2004-05-28 2010-02-12 Fibrogen, Inc. Ensayo de actividad de la prolil hidroxilasa de hif.
GB2421013B (en) 2004-12-10 2007-07-11 Amcor Flexibles Europe As Packaging with an openable top wall
JP4792048B2 (ja) 2005-03-02 2011-10-12 ファイブロゲン インコーポレイティッド チエノピリジン化合物およびその使用方法
CN101849943A (zh) 2005-06-06 2010-10-06 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
EP1919463B9 (en) 2005-06-15 2011-02-02 Fibrogen, Inc. Use of hif 1alfa modulators for treatment of cancer
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
MX2008009581A (es) 2006-01-27 2009-01-07 Fibrogen Inc Compuestos de cianoisoquinolina que estabilizan el factor inducible hipoxia (fih).
CN101420980A (zh) 2006-02-16 2009-04-29 菲布罗根公司 治疗中风的化合物和方法
AU2007234408B2 (en) 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
US20100172984A1 (en) 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
JP5683058B2 (ja) 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
HRP20120085T1 (hr) 2007-10-12 2012-02-29 Astrazeneca Ab Pripravak zibotentana koji sadrži manitol i mikrokristalnu celulozu
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
JP5479949B2 (ja) 2009-04-08 2014-04-23 株式会社東芝 測定装置、測定方法、及び二酸化炭素回収システム
JP2010248106A (ja) 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
US8339523B2 (en) 2010-05-18 2012-12-25 Kabushiki Kaisha Toshiba Television apparatus and electronic apparatus
CN101880914B (zh) 2010-05-25 2012-09-12 中国科学院微电子研究所 利用等离子体浸没离子注入制备黑硅的方法
CN103429239A (zh) 2011-01-13 2013-12-04 菲布罗根有限公司 增加网织红细胞血红蛋白含量的方法
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
US9206134B2 (en) * 2011-07-22 2015-12-08 Beijing Betta Pharmaceuticals Co. Ltd. Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
US20140309256A1 (en) 2011-11-09 2014-10-16 Fibrogen, Inc. Therapeutic Method
SG11201405574UA (en) 2012-03-09 2014-10-30 Fibrogen Inc 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
SMT201800565T1 (it) * 2012-07-16 2018-11-09 Fibrogen Inc Forme cristalline di un inibitore di prolil idrossilasi
US8883823B2 (en) * 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
BR112015001106B1 (pt) 2012-07-16 2021-11-09 Fibrogen, Inc Métodos para a produção de compostos de isoquinolina
TWI685487B (zh) 2013-01-24 2020-02-21 美商費比羅根公司 ｛［１-氰基-５-（４-氯苯氧基）-４-羥基-異喹啉-３-羰基］-胺基｝-乙酸之晶形
RS60464B1 (sr) 2013-06-06 2020-07-31 Fibrogen Inc Farmaceutske formulacije inhibitora hif hidroksilaze

Also Published As

Publication number Publication date
CN103539735B (zh) 2017-08-04
EP2872488A2 (en) 2015-05-20
US20140024676A1 (en) 2014-01-23
SG11201500236SA (en) 2015-02-27
CN104684897A (zh) 2015-06-03
SI2872488T1 (sl) 2018-11-30
US20190276408A1 (en) 2019-09-12
CY1125155T1 (el) 2023-01-05
DK3470397T3 (da) 2022-03-14
KR20150058154A (ko) 2015-05-28
CN107540607A (zh) 2018-01-05
US20200115344A1 (en) 2020-04-16
JP2015522616A (ja) 2015-08-06
MX355428B (es) 2018-04-18
MX2015000504A (es) 2015-07-17
LTC3470397I2 (show.php) 2024-11-11
CN103539735A (zh) 2014-01-29
JP6491093B2 (ja) 2019-03-27
CN114409596A (zh) 2022-04-29
LT3470397T (lt) 2022-02-25
AU2013290438B9 (en) 2018-07-19
DK2872488T3 (en) 2018-10-29
AU2013290438A1 (en) 2015-02-19
CN107501177A (zh) 2017-12-22
RS63122B1 (sr) 2022-05-31
CY1120805T1 (el) 2019-12-11
AU2013290438B2 (en) 2017-09-14
EP3470397B1 (en) 2021-12-29
AU2013290438C1 (en) 2019-01-03
KR102149380B1 (ko) 2020-08-28
CN107382859A (zh) 2017-11-24
CN115093370A (zh) 2022-09-23
SG10202111314YA (en) 2021-12-30
FR22C1030I2 (fr) 2024-08-02
CN109369524A (zh) 2019-02-22
HRP20220182T1 (hr) 2022-04-29
US9115085B2 (en) 2015-08-25
KR20220164068A (ko) 2022-12-12
US10118897B2 (en) 2018-11-06
US20170190667A1 (en) 2017-07-06
US20140303202A9 (en) 2014-10-09
LTPA2022510I1 (show.php) 2022-07-25
ES2689430T3 (es) 2018-11-14
KR20210130849A (ko) 2021-11-01
LT2872488T (lt) 2018-10-25
US9617218B2 (en) 2017-04-11
EP4029854A1 (en) 2022-07-20
ES2905898T3 (es) 2022-04-12
HRP20181751T1 (hr) 2018-12-28
EP2872488B1 (en) 2018-08-22
WO2014014835A8 (en) 2014-11-20
CN107382859B (zh) 2018-09-14
KR102318720B1 (ko) 2021-10-28
IN2015KN00262A (show.php) 2015-06-12
SMT202200095T1 (it) 2022-03-21
CN107501177B (zh) 2018-12-07
NO2022024I1 (no) 2022-06-15
SMT201800565T1 (it) 2018-11-09
PT3470397T (pt) 2022-02-18
EP3470397A1 (en) 2019-04-17
WO2014014835A3 (en) 2014-08-21
HK1243409A1 (zh) 2018-07-13
IL236626B (en) 2020-03-31
CA2879242C (en) 2023-05-09
CA2879242A1 (en) 2014-01-23
HUE057925T2 (hu) 2022-06-28
CN107382860A (zh) 2017-11-24
PT2872488T (pt) 2018-11-22
HUE041458T2 (hu) 2019-05-28
JP2018009034A (ja) 2018-01-18
FR22C1030I1 (fr) 2022-09-09
PL2872488T3 (pl) 2019-01-31
IL236626A0 (en) 2015-02-26
MY182428A (en) 2021-01-25
RS57795B1 (sr) 2018-12-31
PL3470397T3 (pl) 2022-06-20
KR20200102556A (ko) 2020-08-31
BR112015001101A2 (pt) 2017-06-27
US20150322015A1 (en) 2015-11-12
WO2014014835A2 (en) 2014-01-23
SG10201700873UA (en) 2017-04-27
NZ704662A (en) 2017-07-28

Similar Documents

Publication Publication Date Title
HUS2200030I1 (hu) Prolil hidroxiláz inhibitor kristályos alakjai
SMT202200095T1 (it) Forme cristalline di un inibitore di prolil idrossilasi
ZA201400232B (en) Metalloenzyme inhibitor compounds
SG11201405574UA (en) 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
EP2723730A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
SI2892889T1 (sl) Inhibitorske spojine
ZA201309561B (en) Novel inhibitor compounds of phosphodiestarase type 10a
EP2804479A4 (en) METALLOENZYME INHIBITOR COMPOUNDS
HUE037899T2 (hu) Metalloenzim inhibitor vegyületek
ZA201503238B (en) Crystalline forms of a factor xia inhibitor
EP2894981A4 (en) METALLO ENZYME INHIBITOR COMPOUNDS
PL2804858T3 (pl) Związki - inhibitory metaloenzymu
AP3529A (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
IL231269B (en) Preparations for the treatment of HIV
EP2751117A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
GB201211019D0 (en) Inhibitor compounds
EP2748160A4 (en) INHIBITORY COMPOUNDS OF HEPATITIS C
TWI561515B (en) Metalloenzyme inhibitor compounds
ZA201308697B (en) Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors
GB201120474D0 (en) Inhibitors